<DOC>
	<DOCNO>NCT02145494</DOCNO>
	<brief_summary>Giving high dose radiation dominant tumour nodule within prostate hypothesize improve tumour control . This trial ass whether technique , deliver 5 treatment , deliver without increase side effect .</brief_summary>
	<brief_title>The SPARC Trial : Stereotactic Prostate Ablative Radiotherapy Using Cyberknife</brief_title>
	<detailed_description>Aim To assess focal boost deliver dominant tumour nodule alongside 36.25 Gy 5 fraction whole prostate gland . Primary end-point : Acute toxicity ( Radiation Therapy Oncology Group ( RTOG ) , International prostate symptom score ( IPSS ) ) Secondary end-points : Prostate specific antigen ( PSA ) nadir 2-year biochemical control Late toxicity ( IPSS , RTOG , International index erectile function ( IIEF-5 ) ) Quality life ( EQ5D scale ) Inclusion criterion - Prostate cancer patient follow : - PSA &gt; 20 - Gleason grade 4+3 high - Stage T3a - Exclusion criterion - Nodal metastatic disease - PSA &gt; 40 - Stage T3b high Study intervention This phase II study recruit 20 patient . A dose 36.25 Gy 5 fraction deliver whole prostate simultaneous integrate boost 47.5 Gy 5 fraction high dose possible within dose constraint . The boost volume define multiparametric magnetic resonance scan specialist radiologist .</detailed_description>
	<criteria>Prostate cancer patient follow : PSA 2040 Gleason grade 4+3 high Stage T3a Nodal metastatic disease PSA &gt; 40 Stage T3b high</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>SBRT ( stereotactic body radiotherapy )</keyword>
	<keyword>Focal boost</keyword>
	<keyword>Prostate</keyword>
</DOC>